Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Beziehungen zwischen Lateinamerika und den Vereinigten Staaten Beziehungen zwischen der Europäischen Union und den Vereinigten Staaten Amerikanisierung Antiamerikanismus American Studies, interdisziplinäres Wissenschaftsgebiet, das sich mit Geschichte, Politik, Gesellschaft, Kultur und Sprache der Vereinigten Staaten beschäftigt
== Literatur == Patrick J. Deneen: American Odyssey. What an Ancient Story Reveals about Our Divided Soul. Creed & Culture Books, Nashville (Tennessee) 2026, ISBN 978-1-967613-32-8. Andrew Denison, Georg Schild, Miriam Shabafrouz (Hrsg.): Länderbericht USA. Bundeszentrale für politische Bildung, Bonn 2021, ISBN 978-3-7425-0700-6 (bpb.de [EPUB]). Horst Dippel: Geschichte der USA. 11. Auflage. C.H. Beck, München 2021, ISBN 978-3-406-76904-7. Philipp Gassert, Mark Häberlein, Michael Wala: Geschichte der USA. Reclam, Ditzingen 2021, ISBN 978-3-15-014159-5. Thomas Jäger: Die Außenpolitik der USA – Eine Einführung. Springer VS, Wiesbaden 2017, ISBN 978-3-531-13834-3. Christian Lammert, Boris Vormann, Markus B. Siewert (Hrsg.): Handbuch Politik USA. 2. Auflage. Springer VS, Wiesbaden 2020, ISBN 978-3-658-23844-5. Christian Lammert, Christoph M. Haas, Simon Koschut: Politik in den USA -Institutionen – Akteure – Themen. Kohlhammer, Stuttgart 2018, ISBN 978-3-17-030689-9. Karl Schlögel: American Matrix / Besichtigung einer Epoche. Hrsg.: Karl Schlögel. 1. Auflage. Carl Hanser Verlag, München 2023, ISBN 978-3-446-27839-4. Bernd Stöver: Geschichte der USA. 3. Auflage. C.H. Beck, München 2021, ISBN 978-3-406-78295-4.
Literatur von und über Vereinigte Staaten im Katalog der Deutschen Nationalbibliothek Linkkatalog zum Thema Vereinigte Staaten bei curlie.org (ehemals DMOZ) bpb.de: Dossier USA auf dem deutschen Informationsportal zur politischen Bildung Länderprofil des deutschen Statistischen Bundesamtes USA-Länderinformationen des Auswärtigen Amtes der Bundesrepublik Deutschland de.usembassy.gov: Amerikanische diplomatische Vertretungen in der Bundesrepublik Deutschland USA-Info.net America, who are you. Dokumentation auf Arte. Abgerufen am 19. Juli 2026.
Sources: de.wikipedia.org
Die Montanuniversität Leoben (auch MU Leoben, Montanuni und MUL) ist eine Technische Universität, deren Studienrichtungen ihren Schwerpunkt entlang des gesamten Wertschöpfungskreislaufs haben und die an der Entwicklung grüner Technologien arbeitet. Sie ist zudem Österreichs einzige Hochschule für Berg- und Hüttenwesen. Insgesamt können an der Montanuniversität 13 Bachelorstudien und 26 Masterstudien absolviert sowie ein Doktorat in jedem der Fachbereiche erworben werden. Die MU Leoben bildet mit der TU Graz und der TU Wien den Verbund Austrian Universities of Technology (TU Austria) mit mehr als 45.600 Studierenden, 460 Mio. Euro Bilanzsumme und über 11.000 Mitarbeitern.
Sources: de.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.